David R. Shprecher

David R. Shprecher, DO, MSCI, FAAN

Languages spoken: English, Spanish, Japanese

Academic Information

Departments Adjunct - Neurology

Divisions:

Academic Office Information

David.Shprecher@hsc.utah.edu

Board Certification

  • American Board of Psychiatry & Neurology (Neurology)

David Shprecher, DO Msci has dedicated his career to improving treatment options for individuals with movement disorders including ataxia, dystonia, essential tremor, Huntington disease, multiple system atrophy, progressive supranuclear palsy, tardive dyskinesia, tics and Tourette syndrome, Lewy body dementia and Parkinson disease. This includes use of botulinum toxin injections and deep brain stimulation to treat movement disorders.

He has maintained an adjunct position with the University of Utah for clinical trials. His primary practice is now located at the Cleo Roberts Clinic in Sun City, Arizona.

Education History

Fellowship University of Rochester
 Fellow
University of Rochester
 MS
Residency University of Utah School of Medicine
 Resident
University of Utah School of Medicine
 Intern
Professional Medical Lake Erie College of Osteopathic Medicine
 DO
Cornell University College of Arts and Sciences
 BS

Selected Publications

Journal Article

  1. Serrano GE, Walker JE, Tremblay C, Piras IS, Huentelman MJ, Belden CM, Goldfarb D, Shprecher D, Atri A, Adler CH, Shill HA, Driver-Dunckley E, Mehta SH, Caselli R, Woodruff BK, Haarer CF, Ruhlen T, Torres M, Nguyen S, Schmitt D, Rapscak SZ, Bime C, Peters JL, Alevritis E, Arce RA, Glass MJ, Vargas D, Sue LI, Intorcia AJ, Nelson CM, Oliver J, Russell A, Suszczewicz KE, Borja CI, Cline MP, Hemmingsen SJ, Qiji S, Hobgood HM, Mizgerd JP, Sahoo MK, Zhang H, Solis D, Montine TJ, Berry GJ, Reiman EM, Rltgen K, Boyd SD, Pinsky BA, Zehnder JL, Talbot P, Desforges M, DeTure M, Dickson DW, Beach TG (2022). SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19. J Neuropathol Exp Neurol.
  2. Martino D, Malaty I, Mller-Vahl K, Nosratmirshekarlou E, Pringsheim TM, Shprecher D, Ganos C, Movement Disorders Society Tourette Syndrome Study Group (2021). Treatment failure in persistent tic disorders: an expert clinicians' consensus-based definition. Eur Child Adolesc Psychiatry.
  3. Ganos C, Sarva H, Kurvits L, Gilbert DL, Hartmann A, Worbe Y, Mir P, Mller-Vahl KR, Mnchau A, Shprecher D, Singer HS, Deeb W, Okun MS, Malaty IA, Hallett M, Tijssen MA, Pringsheim T, Martino D, Tic Disorders and Tourette Syndrome Study Group of the International Parkinson and Movement Disorder Society (2021). Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. Tremor Other Hyperkinet Mov (N Y), 11, 43.
  4. Parkinson Study Group SURE-PD3 Investigators (2021). Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA, 326(10), 926-939.
  5. Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Mehta SH, Atri A, Caviness JN, Serrano G, Shprecher DR, Sue LI, Belden CM (2020). Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study. Neurol Clin Pract, 11(4), e414-e421.
  6. Litvan I, Proudfoot JA, Martin ER, Standaert D, Riley D, Hall D, Marras C, Bayram E, Dubinsky RM, Bordelon Y, Reich S, Shprecher D, Kluger B, Cunningham C, Schellenberg GD, Jankovic J (2021). Gene-Environment Interactions in Progressive Supranuclear Palsy. Front Neurol, 12, 664796.
  7. Rezvanian S, Litvan I, Standaert D, Jankovic J, Reich SG, Hall D, Shprecher DR, Bordelon Y, Dubinsky R, Kluger B (2020). Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord, 78, 56-60.
  8. Bayram E, Marras C, Standaert DG, Kluger BM, Bordelon YM, Shprecher DR, Litvan I, ENGENE-PSP Consortium (2020). Progressive Supranuclear Palsy and Statin Use. Mov Disord, 35(7), 1253-1257.
  9. Beach TG, Adler CH, Zhang N, Serrano GE, Sue LI, Driver-Dunckley E, Mehta SH, Zamrini EE, Sabbagh MN, Shill HA, Belden CM, Shprecher DR, Caselli RJ, Reiman EM, Davis KJ, Long KE, Nicholson LR, Intorcia AJ, Glass MJ, Walker JE, Callan MM, Oliver JC, Arce R, Gerkin RC (2020). Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. PLoS One, 15(4), e0231720.
  10. Serrano GE, Shprecher D, Callan M, Cutler B, Glass M, Zhang N, Walker J, Intorcia A, Adler CH, Shill HA, Driver-Dunckley E, Mehta SH, Belden CM, Zamrini E, Sue LI, Vargas D, Beach TG (2020). Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease. Brain Commun, 2(1), fcaa004.
  11. Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE (2019). Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry, 90(12), 1317-1323.
  12. Shoeibi A, Litvan I, Juncos JL, Bordelon Y, Riley D, Standaert D, Reich SG, Shprecher D, Hall D, Marras C, Kluger B, Olfati N, Jankovic J (2019). Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? Parkinsonism Relat Disord, 69, 34-39.
  13. Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN, Mehta SH, Sabbagh MN, Serrano GE, Sue LI, Belden CM, Powell J, Jacobson SA, Zamrini E, Shprecher D, Davis KJ, Dugger BN, Hentz JG (2019). Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. J Neuropathol Exp Neurol, 78(10), 891-899.
  14. Rabadia SV, Litvan I, Juncos J, Bordelon Y, Riley DE, Standaert D, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J (2019). Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord, 66, 166-170.
  15. Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE (2019). Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry, 90(12), 1317-1323.
  16. Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, Jacobson SA, Belden CM, Caselli RJ, Woodruff BK, Rapscak SZ, Ahern GL, Shi J, Caviness JN, Driver-Dunckley E, Mehta SH, Shprecher DR, Spann BM, Tariot P, Davis KJ, Long KE, Nicholson LR, Intorcia A, Glass MJ, Walker JE, Callan M, Curry J, Cutler B, Oliver J, Arce R, Walker DG, Lue LF, Serrano GE, Sue LI, Chen K, Reiman EM (2019). Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS One, 14(6), e0217566.
  17. Shprecher D, Zhang N, Halverson M, Savica R (2019). Parkinsonism Risk Factors in Salt Lake City, Utah: A Community-Based Study. Brain Sci, 9(3).
  18. Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross NLangbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB, European Huntingtons Disease Network, HuntingtonStudy Group investigators (2018 Dec 14 [Epub ahead of print]). Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol.
  19. Barrell K, Bureau B, Turcano P, Phillips GD, Anderson JS, Malik A, Shprecher D, Zorn M, Zamrini E, Savica R (2018). High-Order Visual Processing, Visual Symptoms, and Visual Hallucinations: A Possible Symptomatic Progression of Parkinson's Disease. Front Neurol, 9, 999.
  20. Marras C, Cunningham CR, Hou J, Proudfoot J, Standaert DG, Juncos J, Riley D, Reich SG, Hall D, Kluger B, Bordelon Y, Shprecher DR, Litvan I, for ENGENE-PSP (2017). Anti-inflammatory drug use and progressive supranuclear palsy. Parkinsonism Relat Disord, 48, 89-92.
  21. Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, Bordelon Y, Shprecher DR, Reich SG, Hall D, Kluger B, Marras C, Jankovic J, Dubinsky R, Litvan I, ENGENE-PSP Study (2018). Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord, 33(3), 468-472.
  22. Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I (2017). Genetic influences on cognition in progressive supranuclear palsy. Mov Disord, 32(12), 1764-1771.
  23. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE (2017). Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology, 88(21), 2003-2010.
  24. Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J, ENGENE PSP study (2017). Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord, 35, 75-81.
  25. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D (11/8/2016). Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y), 6.
  26. Kious BM, Jimenez-Shahed J, Shprecher DR (2016). Treatment-refractory Tourette Syndrome. Prog Neuropsychopharmacol Biol Psychiatry, 70, 227-36.
  27. Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, ONeill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E (2016). Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA, 316(1), 40-50.
  28. Brody DM, Litvan I, Warner S, Riley DE, Hall DA, Kluger BM, Shprecher DR, Cunningham CR (2016). Relationship between uric acid levels and progressive supranuclear palsy. Mov Disord, 31(5), 663-7.
  29. Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG, Marras C, Juncos J, Riley D, Reich S, Hall D, Kluger B, Bordelon Y, Shprecher DR, for ENGENE-PSP (2016). Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. Mov Disord, 31(5), 644-52.
  30. Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP (2015). The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Mol Neurodegener, 10, 50.
  31. Shprecher D, Rubenstein L, Gannon K, Frank S, Kurlan R (2014). Temporal Course of the Tourette Syndrome Clinical Triad. Tremor Other Hyperkinet Mov (N Y).
  32. Shprecher D, Schrock L, Himle M (2014). Neurobehavioral aspects, pathophysiology, and management of Tourette's syndrome. Curr Opin Neurol, 27(4), 484-92.
  33. Shprecher D, Gannon K, Agarwal N, Shi X, Anderson J (2014). Elucidating the mechanism of tic improvement in Tourette syndrome: a pilot study. Tremor Other Hyperkinet Mov (N Y).
  34. Duff K, Shprecher D, Litvan I, Gerstenecker A, Mast B on behalf of the ENGENE investigators (2013). Correcting for demographic variables on the modified Telephone Interview for Cognitive Status. Am J Geriatr Psychiatry.
  35. Shprecher D, Noyes Katia, Biglan Kevin, Wang Dongwen, Dorsey Ray E, Kurlan Roger, Adams Michael Jacob (2012). Willingness of Parkinson Disease Patients to Participate in Research Using Internet Based Technology. Telemed J E Health.
  36. Dorsey ER, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM (2010). A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups. Mov Disord, 25(13), 2128-35.
  37. Shprecher D, Mehta L (2010). The syndrome of delayed post-hypoxic leukoencephalopathy. NeuroRehabilitation, 26(1), 65-72.
  38. Shprecher D, Kurlan R (2009). The management of tics. Mov Disord, 24(1), 15-24.
  39. Shprecher DR, Flanigan KM, Smith AG, Smith SM, Schenkenberg T, Steffens J (2008). Clinical and diagnostic features of delayed hypoxic leukoencephalopathy. J Neuropsychiatry Clin Neurosci, 20(4), 473-7.
  40. Shprecher D, Schwalb J, Kurlan R (2008). Normal pressure hydrocephalus: diagnosis and treatment. Curr Neurol Neurosci Rep, 8(5), 371-6.

Review

  1. Lyon G, Shprecher D, Coffey B, Kurlan R (July 2010). Tourette’s Disorder. [Review]. Curr Treat Options Neurol, 12(4), 274-286.

Case Report

  1. Shprecher D, Grossmann K, Tward J (2014). Sustained remission of Parkinson disease associated melanoma with immunotherapy. Parkinsonism Relat Disord.

Editorial

  1. Shprecher DR, Majersik JJ (2017). The virtual house call: A 21st-century innovation in the care of patients with Parkinson disease. Neurology, 89(11), 1103-1104.